The spread of plasmid borne resistance enzymes in clinical Staphylococcus aureus isolates is rendering trimethoprim and iclaprim, both inhibitors of dihydrofolate reductase (DHFR), ineffective. Continued exploitation of these targets will require compounds that can broadly inhibit these resistance-confering isoforms. Using a structure-based approach, we have developed a novel class of ionized non-classical antifolates (INCAs) that capture the molecular interactions that have been exclusive to classical antifolates. These modifications allow for a greatly expanded spectrum of activity across these pathogenic DHFR isoforms, while maintaining the ability to penetrate the bacterial cell wall. Using biochemical, structural and computational methods, we are able to optimize these inhibitors to the conserved active sites of the endogenous and trimethoprim resistant DHFR enzymes. Here, we report a series of INCA compounds that exhibit low nanomolar enzymatic activity and potent cellular activity with human selectivity against a panel of clinically relevant TMP R MRSA isolates.
compound, iclaprim, a structurally similar DHFR inhibitor with anti-staphylococcal activity, has 24 recently completed a Phase III clinical trial for acute bacterial skin and skin structure (ABSSI) 25 infections 4 . DHFR inhibitors are historically grouped into two classes: lipophilic and classical. 26
Trimethoprim and iclaprim are lipophilic antifolates as they contain a 2,4-diaminopyrimidine 27 pharmacophore and passively diffuse into the cytosolic space. Methotrexate and pemetrexed, both 28 chemotherapeutics, are known as classical antifolates as they possess a glutamate moiety in their 29 structure, Figure 1 . As mimics of the natural substrate DHF, classical antifolates show high affinity 30 to all DHFR enzymes, however due to the negatively charged glutamate tail (net charge= -2), these 31 compounds must be actively transported into the cell via specific folate carriers. Since bacteria do 32 not have these transport mechanisms, classical antifolates do not show significant antibacterial 33 efficacy despite powerful inhibition of bacterial DHFR. South Africa where its import to Europe was tracked via epidemiological studies 7, 8 . dfrK, encoding 48 the protein DfrK, was predominately associated with agricultural, specifically swine associated 49 infections and began recently appearing in farmers and children in farm villages in Ireland 9 . We 50 recently identified dfrG and dfrK in clinical strains of MRSA from Connecticut hospitals, with 51 dfrG being the predominant resistance determinant 10 . Our observations were mimicked in other 52 studies identifying DfrG in as many as 78% of TMP R isolates followed by dfrA, dfrK variants. 53
Strains with mutant DfrB were seldom isolated 11, 12 . 54
We have been developing next generation DHFR inhibitors against TMP-resistant Gram-55 positive 13, 14 , 16 and mycobacterial 17 pathogens. These compounds feature a 6-56 ethyl-2,4-diaminopyrimidine moiety linked to a meta-biaryl system through an acetylenic linker 57 ( Figure 1 ). Recently, we disclosed a distinct class of antifolates designated as ionized non-classical 58
antifolates (INCA) , that are characterized by acidic functionality in the C-ring to capture the 59 powerful interaction between the glutamate tail of classical antifolates and DHFR 14 . Importantly, 60 this modification alters the charge distribution of INCAs to anionic/zwitterionic relative to earlier 61 generations that are cationic/neutral. Additionally, this mono-carboxylate design allows us to 62 exploit the key interactions used in substrate/classical antifolate binding while still maintaining the 63 within the active site. With the exception of a Leu5 to Ile substitution in the DfrA, DfrG, and DfrK 88 proteins, the residues which make hydrogen bonds to the substrate, Glu27, Phe92 and Arg57, 89 remain conserved throughout the acquired enzymes. A sequence alignment is reported in 90
Supplemental Figure S2 . DfrG and DfrK also contain the Tyr98 and Tyr149 substitutions. 91
Mutations at these three of these positions are known to confer TMP resistance in the chromosomal 92 DfrB enzyme 18 . 93
All clinical isolates used in this study exhibit high levels of antifolate resistance, Table 1 . The dfrG 94 and dfrK containing isolates, UCH121 and HH184, exhibited the highest levels of resistance to 95 both trimethoprim and iclaprim with MIC values of >1000 μg/mL and >250 μg/mL, respectively. 96
The dfrA containing strain, UCH115, also succumbs to high level antifolate resistance with MIC 97 values of 250 μg/mL for trimethoprim and 64 μg/mL for iclaprim. Minimally, the presence of these 98 resistant enzymes in the clinical isolates results in an 800-fold loss in cellular efficacy when 99 compared to the TMP S comparator, ATCC 43300. Overall, iclaprim is unable to evade any of these 100 prevalent TMP resistant elements rendering the compound largely ineffective against existing 101 TMP R isolates. 102 103 Figure 2 . 136 Through structure-based drug design, we have been able to establish a preliminary structure 137 activity relationship between these benzoic acid inhibitors, interactions with Arg57 and potency. 138
Crystal structures of the first-generation carboxylate compounds with an unsubstituted propargylic 139 position indicated a highly coordinated water network between the para-benzoic acid and Arg57. 140
Branching from the propargylic carbon with a simple methyl group displaces the biaryl system 141 toward the Arg57 residue effectively disrupting the water network and forming one direct 142 hydrogen bonding and one water-mediated interaction with the guanidinium side chain. antifolates. Moreover, the potential value of adding this functionality to antibacterial agents has 167 been recognized as a tool to overcome resistance to point mutations, as this residue is unlikely to 168 mutate without encountering a major fitness cost 22 . 169 carboxylate would allow for a more productive MTX-like interaction. Therefore, a matched series 171 of five benzoic acid and phenyl acetic acid inhibitors were synthesized, following previously 172 reported synthetic strategies, for structural, biochemical and microbiological evaluations, Table  173 3. 13, 16 174 These compounds demonstrated excellent inhibitory affinity (Ki values <1.2 nM) toward the wild-177 type enzyme, DfrB. In the case of the benzoic acid series, introducing a R1,R2-dioxolane (1271) 178 substituted B-ring enhanced the enzymatic inhition by 10-fold relative to a R1-OCH3 (1273) 179 substituted compound. In addition, replacing the R1-OCH3 with a R1-Cl (1229) acid analog. This observation supported our hypothesis that increase in proximity and flexibility 185 creates better interactions between the ionized extended-carboxylates and the conserved arginine. 186
When evaluated against TMP R enzymes, the INCAs were >1000-fold more potent than TMP and 187 showed over 100-fold greater inhibitory activity relative to iclaprim against DfrA, DfrG and DfrK. 188
Changing the B-ring substitution from R1-OMe to a R1, R2-dioxolane or R1-Cl had a positive effect 189 across all three enzymes. Notably, 1229 showed 3, 215 and 150-fold increases in enzyme inhibition 190 Table S1 . isolates. Overall, these compounds maintained potent activity against wild-type ATCC43300 213 quality control strains with MIC vaues between 0.4 and <0.001 µg/mL, with the R1-Cl inhibitors 214 (1229 and 1247) being most potent with MICs below 1 ng/mL. In general, the extension from 215 benzoic acid to phenyl acetic acid had only a minor effect (1-2 fold increase) on potencies against 216 the wild-type strain. Interestingly, MIC values for UCH121 and HH1184, which contain the dfrG 217 and dfrK resistance genes, range from 0.625-10 and 0.3125 -2.5µg/mL, respectively. The most 218 active compounds from the benzoic acid series exhibited a >400 and >1,600-fold increase in 219 potency compared to iclaprim and trimethoprim, respectively. For these strains, the majority of the 220 phenyl acetic acid series were comparable or within two fold of their benzoic acid partner. 221 MIC values for the dfrA containing strain, UCH115 range from 1.25-20µg/mL, a 200 and 500-fold 222 increase in activity when compared to trimethoprim and iclaprim. Moreover, for UCH115, the 223 extended acids exhibited a moderate increase in potency over the benzoic acid analogs. Figure S3) . 252
253

Structural and Computational Studies 254
To aid in the understanding of the observed efficacy and to guide future optimization efforts, 255 several crystal structures with lead compounds, 1232 and 1267, bound to the wild type S. aureus 256 DHFR were solved. Crystals of DfrB:NADPH:1232 and DfrB:NADPH:1267 diffracted to 1.65Å 257 and 2.73Å, respectively. Data collection and refinement statistics are presented in Table S1 . The 258 structure of the DfrB:NADPH:1232 complex revealed the standard five hydrogen bonding 259 interactions between the 6-ethyl diaminopyrimidine and Asp27 side chain (2.6Å and 3.1Å), an 260 active site water (3.0Å), Phe92 (3.1Å), and Leu5 (3.0Å) backbone carbonyls. This configuration 261 also enables the compound to form several hydrophobic interactions between the Phe92, Leu28, 262
Val31, Ile50 and Leu54 side chains. Additionally, the carboxylic moeity extends to form the 263 intended dual hydrogen bonding interactions with the Arg 57 side chain, one at 2.6Å and the other 264 at 3.1Å, Figure 3 Finally, we were interested in examining the conformational re-organization that these ligands 312 undergo upon binding with bacterial DHFR and evaluating their associated energy penalties. 313 Therefore, two different dihedrals angles, the dihedral angle between propargylic methyl and the 314 aromatic B ring, and the dihedral angle between aromatic B and C rings were chosen for analysis. 315
Molecular dynamic calculations performed on a paired set of benzoic acid and phenyl acetic acid 316 ligands, 1191 and 1232 generated two separate minimum energy conformers for each ligands and 317
were further compared with their bioactive conformers. We observed (Supplemental Table 3 and 318 the narrow dihedral angles (4 to-18 o ) between propargylic methyl and aromatic B-ring were well 320 tolerated in all of the bioactive conformers overriding the conformational bias of larger (99 to110 o ) 321 dihedral angles in the minimum energy structures. In order to make optimal interactions with the 322 distal arginine via the dual H-bonding this dihedral angle expanded from 3. antifolates that capture a key electrostiatic interaction common to classical antifolates without 332 compromising the bacterial permeability associated with lipophilic antifolates. Moreover, 333 structure-activity realtionships indicate that it should still be possible to achieve target-level 334 selectivity even when exploiting this highly conserved interaction. It is noteworthy that developing 335 compounds that simultaneously target both the endogenous and acquired enzymes has been a 336 successful approach for the treatment of MRSA with 5 th generation cephalosporins, which unlike 337 the earlier generation cephalosporins, target the both the endogenous PBPs as well as the acquired 338
PBP2a. 339
Crystal structures of the INCA compounds disclosed here indicate several highly coordinated 340 hydrogen bonding interactions between the inhibitor and enzyme active site, several of which have, 341 of this antifolate class revealed a highly coordinated water network between the distal region of 343 the inhibitor and the Arg57 residue of DfrB. Lead by crystal structures and biochemical 344 evaluations, optimization of the proximal ring system and propargylic position allowed us to 345 displace the water network to form a single hydrogen bonding interaction to displace the water 346 network to form a single hydrogen bond and one water mediated interaction with the active site. INCAcompounds (all in DMSO) were determined following CLSI broth dilution guidelines using 361 isosensitest broth and an inoculum of 5x10 5 CFU/mL 32 . MIC values were determined as the lowest 362 concentration of inhibitor to prevent visible cell growth after 18 hour incubation at 37 o C. 363
Enzymatic Activity and Inhibition Assays 364 methods 10, 13, 14 . Assays are performed at room temperature in a buffer solution 20 mM TES, pH 366 7.5, 50 mM KCl, 0.5 mM EDTA, 10 mM beta-mercaptoethanol and 1mg/mL BSA. For enzymatic 367 assays (500 μL volume reactions), 1 μg of protein is mixed with 100 μM of NADPH and the 368 reaction is activated with 100μM DHF (in 50 mM TES, pH 7.0). The reaction is monitored in a 369 spectrophotometer at A340. The steady-state kinetic parameters of KM (DHF) and Ki DHF were obtained 370 for TMP R enzymes and compared to the wild type DHFR. Michaelis-Menten constants (KM 371 and Vmax) were graphically determined for the substrate from the initial rates at various DHF 372 concentration (1.6 to 100 μM) and NADPH saturation (100 μM), using a non-linear least-squares 373 fitting procedure 33 . The turnover number (kcat) was calculated on the basis of the enzyme molecular 374 mass. Ki DHF values were obtained using Cheng-Prusoff equation 34 . The reported data are averages 375 of two independent experiments, where each experiment was conducted in triplicates. 376 All data were collected at Stanford Synchrotron Radiation Light (SSRL), SLAC National 424 Accelerator Laboratory. Data were indexed using HKL2000. Phaser was used to identify 425 molecular replacement solutions using PDB ID: 3F0Q Schaumburg, F., Hofmann-Eifler, J., Van Genderen, P.J., Caumes, E., Fleck, R., 506
Mockenhaupt, F.P., Herrmann, M., Kern, W. V., Abdulla, S., Grobusch, M.P., Kremsner 507 P.G., Wolz, C., Zanger, P. 2014. Emergence of trimethoprim resistance gene dfrG in 508 
